Raymond Deen, DO
Family Medicine · Milledgeville, GANPI 1659719722
Payments from drug & device makers
Across 162 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$402
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$292
- AbbVie$238
- Lilly USA, LLC$230
- Novo Nordisk$183
- Pfizer$168
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,757100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $402 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $292 |
| AbbVie(2 entities) | 12 | $238 |
| Lilly USA, LLC | 14 | $230 |
| Novo Nordisk | 11 | $183 |
| Pfizer | 11 | $168 |
| GSK | 11 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $133 |
| Biohaven Pharmaceuticals, Inc. | 5 | $98 |
| Abbott | 4 | $90 |
| Johnson & Johnson | 7 | $85 |
| Idorsia Pharmaceuticals US Inc | 4 | $84 |
| Exact Sciences | 5 | $82 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $72 |
| Boehringer Ingelheim | 5 | $71 |
| Amgen | 4 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $51 |
| Corcept Therapeutics | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Edwards Lifesciences | 1 | $37 |
| Dexcom, Inc. | 2 | $35 |
| Seqirus USA Inc | 1 | $23 |
| Biogen | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$2,763 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $158,488 |
| EliquisApixaban | 141 | $123,312 |
| MounjaroTirzepatide | 88 | $90,683 |
| XareltoRivaroxaban | 52 | $52,835 |
| TrulicityDulaglutide | 50 | $48,249 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $42,449 |
| EntrestoSacubitril/Valsartan | 27 | $23,379 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $22,216 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $19,465 |
| LinzessLinaclotide | 18 | $16,809 |
| MyrbetriqMirabegron | 17 | $14,469 |
| JanuviaSitagliptin Phosphate | 18 | $12,361 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,637 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,487 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $183 | $158,488136 claims |
| Lilly USA, LLCMounjaro, Trulicity | $230 | $138,932138 claims |
| PfizerEliquis | $168 | $123,312141 claims |
| Johnson & JohnsonXarelto | $85 | $52,83552 claims |
| GSKTrelegy Ellipta | $164 | $42,44957 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $402 | $28,70347 claims |
| AbbVieLinzess | $238 | $16,80918 claims |
| Boehringer IngelheimStiolto Respimat | $71 | $5,65112 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $14 | $4,01812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Milledgeville
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.